ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levelsELI-002 7P generated an mKRAS-specific T cell response in 100% of patients including responses targeting all mKRAS mutations enrolled (G12D, V, R and G13D) mKRAS-specific T cells were polyfunctional with 66.7% (4/6) of evaluable patients having both CD8+ and CD4+ responses at the 4.9 mg Phase 2 dose levelTumor biomarker reductions were observed in 5/7 (71%) of evaluable patients at the 4.9 mg Phase 2 dose levelELI-002 7P was shown to induce antigen-spreading with increased T cell responses targeting non-immunizing, personalized tumor neoantigens in 6/6 (100%) of evaluable patients at the 4.9 mg Phase 2 dose level BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc.

ELI-002 7P作为单一疗法给药的耐受性良好，能够产生相对于基线水平约100倍的mKRAS特异性扩增T细胞应答。ELI-002 7P在100%的患者中产生了mKRAS特异性T细胞应答，包括针对所有登记的mKRAS突变（G12D，V，R和G13D）的应答。mKRAS特异性T细胞具有多功能性，其中66.7%（4/6）的可评估患者在4.9 mg 2期剂量水平同时具有CD8+和CD4+应答。在4.9 mg 2期剂量水平的可评估患者中，有5/7（71%）的肿瘤生物标志物减少。显示了ELI-002 7P 2024年5月23日，波士顿（GLOBE NEWSWIRE）——Elicio Therapeutics，Inc。在4.9 mg 2期剂量水平的6/6（100%）可评估患者中，通过增加针对非免疫性个性化肿瘤新抗原的T细胞反应诱导抗原扩散。

(Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P, in a poster presentation at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, being held May 31-June 4, 2024, in Chicago, IL.

（纳斯达克：ELTX，“Elicio Therapeutics”或“Elicio”），一家临床阶段生物技术公司，开发了一系列用于治疗癌症的新型免疫疗法，今天在2024年5月31日至6月4日于伊利诺伊州芝加哥举行的美国临床肿瘤学会（“ASCO”）年会上的海报展示中宣布了正在进行的AMPLIFY-7P 1a期研究的初步数据，该研究是针对其现成的研究性治疗性癌症疫苗候选物ELI-002 7P。

The preliminary data showed ELI-002 7P was well tolerated with T cell responses correlating with a reduction in tumor biomarkers at the recommended Phase 2 dose (“RP2D”). The AMPLIFY-7P study is evaluating the 7-peptide formulation of Elicio’s cancer vaccine candidate, ELI-002 7P, in patients with mKRAS-driven solid tumors that are positive for minimal residual disease following standard locoregional treatment.

初步数据显示，在推荐的2期剂量（“RP2D”）下，ELI-002 7P对T细胞反应的耐受性良好，与肿瘤生物标志物的减少相关。AMPLIFY-7P研究正在评估Elicio癌症疫苗候选物ELI-002 7P的7肽制剂，用于标准局部治疗后对微小残留病呈阳性的mKRAS驱动的实体瘤患者。

ELI-002 7P was developed with Elicio’s proprietary lymph node-targe.

ELI-002 7P是使用Elicio专有的淋巴结靶点开发的。